Hualan Biological Engineering Future Growth
Future criteria checks 2/6
Hualan Biological Engineering is forecast to grow earnings and revenue by 18% and 16.7% per annum respectively. EPS is expected to grow by 19.1% per annum. Return on equity is forecast to be 12.7% in 3 years.
Key information
18.0%
Earnings growth rate
19.1%
EPS growth rate
Biotechs earnings growth | 57.3% |
Revenue growth rate | 16.7% |
Future return on equity | 12.7% |
Analyst coverage | Good |
Last updated | 23 Dec 2024 |
Recent future growth updates
Recent updates
Lacklustre Performance Is Driving Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E
Dec 30Hualan Biological Engineering (SZSE:002007) Seems To Use Debt Quite Sensibly
Nov 18Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 36% Below Their Intrinsic Value Estimate
Oct 07Why Investors Shouldn't Be Surprised By Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E
Aug 22Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 37% Below Their Intrinsic Value Estimate
Jun 26Hualan Biological Engineering's (SZSE:002007) Dividend Will Be CN¥0.30
Jun 09These 4 Measures Indicate That Hualan Biological Engineering (SZSE:002007) Is Using Debt Safely
Jun 07Lacklustre Performance Is Driving Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E
May 21Is Hualan Biological Engineering (SZSE:002007) Using Too Much Debt?
Feb 27Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 7,108 | 1,961 | 2,324 | 1,826 | 8 |
12/31/2025 | 6,103 | 1,691 | 2,476 | 1,642 | 10 |
12/31/2024 | 5,136 | 1,362 | 1,627 | 2,130 | 7 |
9/30/2024 | 4,920 | 1,338 | 436 | 1,113 | N/A |
6/30/2024 | 5,409 | 1,395 | 256 | 900 | N/A |
3/31/2024 | 5,249 | 1,392 | 346 | 1,027 | N/A |
12/31/2023 | 5,342 | 1,482 | 592 | 1,346 | N/A |
9/30/2023 | 4,828 | 1,243 | 807 | 1,538 | N/A |
6/30/2023 | 3,753 | 1,020 | 1,099 | 1,713 | N/A |
3/31/2023 | 4,757 | 1,194 | 835 | 1,268 | N/A |
1/1/2023 | 4,517 | 1,076 | 563 | 957 | N/A |
9/30/2022 | 4,677 | 1,139 | 136 | 662 | N/A |
6/30/2022 | 5,497 | 1,425 | 54 | 704 | N/A |
3/31/2022 | 4,453 | 1,277 | 474 | 1,225 | N/A |
1/1/2022 | 4,436 | 1,299 | 621 | 1,432 | N/A |
9/30/2021 | 5,311 | 1,709 | 1,016 | 1,642 | N/A |
6/30/2021 | 4,925 | 1,559 | 907 | 1,594 | N/A |
3/31/2021 | 4,969 | 1,621 | 764 | 1,495 | N/A |
12/31/2020 | 5,023 | 1,613 | 704 | 1,325 | N/A |
9/30/2020 | 4,134 | 1,284 | 608 | 1,166 | N/A |
6/30/2020 | 3,684 | 1,288 | 902 | 1,295 | N/A |
3/31/2020 | 3,682 | 1,271 | 953 | 1,271 | N/A |
12/31/2019 | 3,700 | 1,283 | 1,090 | 1,363 | N/A |
9/30/2019 | 3,819 | 1,344 | 1,088 | 1,334 | N/A |
6/30/2019 | 3,418 | 1,194 | 1,214 | 1,451 | N/A |
3/31/2019 | 3,351 | 1,192 | 1,255 | 1,440 | N/A |
12/31/2018 | 3,217 | 1,140 | 1,109 | 1,293 | N/A |
9/30/2018 | 2,738 | 961 | 746 | 864 | N/A |
6/30/2018 | 2,556 | 843 | N/A | 590 | N/A |
3/31/2018 | 2,392 | 773 | N/A | 308 | N/A |
12/31/2017 | 2,368 | 821 | N/A | 177 | N/A |
9/30/2017 | 2,195 | 792 | N/A | 146 | N/A |
6/30/2017 | 2,091 | 801 | N/A | 120 | N/A |
3/31/2017 | 2,061 | 843 | N/A | 203 | N/A |
12/31/2016 | 1,935 | 780 | N/A | 330 | N/A |
9/30/2016 | 1,767 | 737 | N/A | 443 | N/A |
6/30/2016 | 1,671 | 690 | N/A | 585 | N/A |
3/31/2016 | 1,585 | 632 | N/A | 549 | N/A |
12/31/2015 | 1,472 | 589 | N/A | 549 | N/A |
9/30/2015 | 1,386 | 575 | N/A | 501 | N/A |
6/30/2015 | 1,372 | 563 | N/A | 429 | N/A |
3/31/2015 | 1,263 | 514 | N/A | 429 | N/A |
12/31/2014 | 1,243 | 538 | N/A | 497 | N/A |
9/30/2014 | 1,237 | 547 | N/A | 541 | N/A |
6/30/2014 | 1,141 | 530 | N/A | 501 | N/A |
3/31/2014 | 1,104 | 519 | N/A | 503 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 002007's forecast earnings growth (18% per year) is above the savings rate (2.8%).
Earnings vs Market: 002007's earnings (18% per year) are forecast to grow slower than the CN market (25.2% per year).
High Growth Earnings: 002007's earnings are forecast to grow, but not significantly.
Revenue vs Market: 002007's revenue (16.7% per year) is forecast to grow faster than the CN market (13.4% per year).
High Growth Revenue: 002007's revenue (16.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 002007's Return on Equity is forecast to be low in 3 years time (12.7%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/23 09:44 |
End of Day Share Price | 2025/01/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hualan Biological Engineering Inc. is covered by 40 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Ethan Cui | BofA Global Research |
Min Luo | Central China Securities Co., Ltd. |
Shuchang Liu | Changjiang Securities Co. LTD. |